Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3231404 | 0.83 | KMT2A (0.49) | KMT2AMEN1RAB9AALDH1A1NPC1 | |
| SCHEMBL1334906 | 0.73 | CYP11B1 (0.38) | KMT2AALDH1A1POLBGAA | |
| SCHEMBL16401839 | 0.73 | MEN1 (0.51) | FKBP1AKMT2AMEN1ALDH1A1RECQL | |
| SCHEMBL16401533 | 0.71 | GSK3B (0.55) | FKBP1AKMT2AMEN1ALDH1A1 | |
| SCHEMBL10931572 | 0.71 | KMT2A (0.40) | KMT2A | |
| SCHEMBL3240144 | 0.70 | ELANE (0.37) | RAB9AALDH1A1NPC1 | |
| SCHEMBL1326182 | 0.70 | RAB9A (0.58) | FKBP1AKMT2AMEN1RAB9ARXRA | |
| SCHEMBL20511984 | 0.69 | FKBP1A (0.42) | FKBP1AKMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL16401840 | 0.69 | FKBP1A (0.42) | FKBP1AKMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL21186 | 0.68 | NOTUM (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | claimed |
| EP-3004131-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM Chemicals Llc (US) | 2016-04-13 | — | — | EP | claimed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | claimed |
| WO-2014197714-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2014-12-11 | — | — | WO | claimed |
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2018-12-20 | — | — | US | disclosed |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3004131-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM Chemicals Llc (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2014197714-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, FBP1, PNKP | FKBP1A 3387/4885KMT2A 2198/4885MEN1 724/4885 |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | FKBP1A 3913/4885KMT2A 2408/4885MEN1 873/4885 |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, TYMP, PAICS | FKBP1A 3913/4885KMT2A 2408/4885MEN1 873/4885 |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | FKBP1A 3913/4885KMT2A 2408/4885MEN1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.